麦角新碱联合米索前列醇治疗前置胎盘的临床疗效及对血清ROS、SOD、GSH-px水平的影响

Curative Efficacy of Ergosine Plus Misoprostolin in the Treatment of Placenta Previa and Its Effects on the Serum ROS, SOD and GSH-px Levels

目的:分析麦角新碱联合米索前列醇治疗前置胎盘的临床疗效及对血清活性氧(ROS)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-px)水平的影响。方法:选择2016年5月-2017年5月我院收治的前置胎盘患者100例纳入本次研究,根据随机分组法分为观察组(n=52)和对照组(n=48)。对照组使用米索前列醇治疗,观察组采用麦角新碱联合米索前列醇进行治疗。比较两组患者的临床疗效、治疗前后血清ROS、SOD、GSH-px水平的变化、术中、术后出血量、止血时间及不良反应的发生情况。结果:治疗后,两组患者的总有效率分别为96.15%、81.25%,观察组显著高于对照组(P<0.05);两组患者血清ROS、SOD、GSH-px水平均较治疗前显著改善,且观察组患者血清ROS低于对照组,血清SOD、GSH-px水平显著高于对照组(P<0.05);观察组患者术中、术后出血量及止血时间均显著低于对照组(P<0.05);两组患者不良反应总发生率分别为7.69%、22.92%,观察组显著低于对照组(P>0.05)。结论:麦角新碱联合米索前列醇治疗前置胎盘的疗效和安全性均显著优于单用米索前列醇治疗,可能与其有效改善血清ROS、SOD、GSH-px水平有关。

Objective:To study the curative efficacy of Ergosine plus misoprostol in the treatment of Placenta previa and its effects on the serum Reactive oxygen species(ROS),superoxide dismutase(SOD),glutathione peroxidase(gsh-px)levels.Methods:100 cases of placenta previa patients admitted to our hospital from May 2016 to May 2017 were selected and divided into the observation group(n=52)and the control group(n=48)according to the random grouping method.The control group was treated with misoprostol,while the observation group was treated with ergoxin combined with misoprostol.The clinical efficacy,changes of serum ROS,SOD and GSH-px levels before and after treatment,intraoperative and postoperative blood loss,hemostasis time and incidence of adverse reactions were compared between the two groups.Results:After treatment,the total effective rates of observation group and control group were96.15%and 81.25%,respectively,which was significantly higher in the observation group than that of the control group(P<0.05).The levels of serum ROS,SOD and GSH-px in the two groups were significantly improved compared with those before treatment,and the levels of serum ROS in the observation group were lower than those in the control group,the levels of serum SOD and gsh-px were significantly higher than those in the control group(P<0.05).The intraoperative and postoperative blood loss and hemostasis time in the observation group were significantly lower than those in the control group(P<0.05).The total incidence of adverse reactions in the two groups was 7.69%and 22.92%,respectively,which was significantly lower in the observation group than that of the control group(P>0.05).Conclusion:The efficacy and safety of ergoxin combined with misoprostol in the treatment of placenta previa are significantly better than those of misoprostol alone,which may be related to the effective improvement of serum ROS,SOD and GSH-px levels.